A Phase 1, Open Label Study To Evaluate The Pharmacokinetics, Pharmacodynamics, And Effect On QT/QTc Interval For CP-751,871 Following Single Intravenous Administration To Healthy Adult Subjects.

Trial Profile

A Phase 1, Open Label Study To Evaluate The Pharmacokinetics, Pharmacodynamics, And Effect On QT/QTc Interval For CP-751,871 Following Single Intravenous Administration To Healthy Adult Subjects.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 May 2013

At a glance

  • Drugs Figitumumab; Moxifloxacin
  • Indications Bacterial infections; Breast cancer; Colorectal cancer; Gastrointestinal cancer; Gynaecological cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Sarcoma; Solid tumours
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 01 May 2010 Planned end date changed from 1 Mar 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
    • 07 Nov 2009 Planned number of patients changed from 72 to 28 as reported by ClinicalTrials.gov.
    • 07 Nov 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top